
Sign up to save your podcasts
Or


Dr. Pedro Barata and Dr. Bridget Keenan discuss the innovative bioengineering allowing clinicians to target historically "immune-cold" tumors, the logistical evolution of bringing bispecific therapies safely into outpatient community clinics, and the complex future of predictive biomarkers and resistance mechanisms.
LINK TO FULL TRANSCRIPT
By American Society of Clinical Oncology (ASCO)4.5
3131 ratings
Dr. Pedro Barata and Dr. Bridget Keenan discuss the innovative bioengineering allowing clinicians to target historically "immune-cold" tumors, the logistical evolution of bringing bispecific therapies safely into outpatient community clinics, and the complex future of predictive biomarkers and resistance mechanisms.
LINK TO FULL TRANSCRIPT

319 Listeners

40 Listeners

17 Listeners

58 Listeners

3,364 Listeners

46 Listeners

340 Listeners

24 Listeners

229 Listeners

59 Listeners

472 Listeners

60 Listeners

196 Listeners

47 Listeners

4,360 Listeners